LAKEWOOD, Colo.--(BUSINESS WIRE)--CaridianBCT, a leading global provider of technology, products and services in automated blood collections, therapeutic systems, whole blood processes and pathogen reduction technologies, announced today that it has initiated a clinical trial for treating whole blood with Mirasol Pathogen Reduction Technology (PRT) after receiving clearance from the U.S. Food and Drug Administration (FDA) and U.S. Department of Defense. The Mirasol PRT system is a proprietary technology that uses riboflavin and UV light to reduce the levels of infectious pathogens and inactivate white cells from collected blood, improving the safety of transfused blood.
